Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/680267


Taiwan Pharmaceuticals and Healthcare Report Q4 2008


Description: Our Taiwan Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Taiwan's pharmaceuticals and healthcare industry.

Taiwan’s US$4.29bn pharmaceutical market is characterised by a universal healthcare scheme, a nascent biotechnology sector, increasing use of generic drugs, and occasional price cuts. The author is projecting a compound annual growth rate of 7.05% through to 2012, when the sector will have a valuation of US$6.03bn.

Taiwanese doctors are enthusiastic prescribers of medicine. A Department of Health survey from June 2008 revealed that drug fees accounted for nearly one quarter of the total National Health Insurance (NHI) expenditure. In comparison, US-based healthcare insurers spent just 15% of income on pharmaceuticals.

According to a National Health Research Institute survey, 12% of the Taiwan population – or 2mn people – are suffering from chronic kidney disorders. Moreover, only 3.5% are aware of their condition. This figure increases to 20% in the lower social-economic class. Globally, Taiwan has the highest percentage of population in need of dialysis treatments, which costs US$920mn a year. Taiwan’s legislative body approved the protocol amending the World Trade Organisation (WTO)’s Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement in June 2008. This allowed the export of drugs to fulfil compulsory licenses issued by developing countries.

The emerging medical tourism industry in Taiwan will benefit from the initiation of direct flights from China in July 2008. Rather than an enforced stopover, visitors from the mainland seeking high-quality healthcare can now fly straight to Taipei and seven other Taiwanese cities. However, it is our view that the upside will be marginal until visa rules are relaxed. Taiwan’s medicine manufacturing sector has had a challenging few years. Competition from China and India, combined with fluctuating prices of raw materials, has resulted in erratic output. However, new data from the Industry and Technology Intelligence Services (ITIS), combined with our projections, reveal that the value of finished drugs, active pharmaceutical ingredients (APIs) and traditional Chinese medicines (TCMs) produced in Taiwan this year will surpass the record set in 2003.


Contents: Executive Summary
Taiwan Pharmaceuticals And Healthcare Industry SWOT
Taiwan Political SWOT
Taiwan Economic SWOT
Taiwan Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q408
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Table: Examples Of Controlled Drugs In Taiwan
Table: Medicine Categories In Taiwan
Recent Regulatory Developments
Intellectual Property Regime
Intellectual Property Developments
Compulsory Licensing
Pricing Regime
Price Cuts
Reimbursement Regime
Table: Drug Reimbursement Principles
Recent Reimbursement Developments
Free Trade Agreements
Industry Trends And Developments
Epidemiology
Recent Public Health Developments
Healthcare System
Table: Premium Contribution For Taiwan's Bureau Of National Health Insurance (% share)
Domestic Pharmaceutical Sector
Foreign Company Activity
Traditional Chinese Medicine
Biotechnology Sector
Recent Biotechnology Developments
Medical Tourism
Vaccines
Recent Developments In The Vaccines Market
Medical Devices
Table: Taiwan Medical Device Market Forecast (US$bn unless otherwise stated)
Recent Developments In The Medical Devices Market
Industry Forecast Scenario
Overall Market Forecast
Table: Drug Expenditure And Prescription Market Indicators (TWDmn unless otherwise stated)
Key Growth Factors – Industry
Table: Taiwan’s Health Expenditure Forecast Indicators
Key Growth Factors – Macroeconomic
Table: Taiwan – Economic Activity
Patented Market Forecast
Table: Taiwan’s Patented Drug Market Indicators
Generics Market Forecasts
Table: Taiwan’s Generics Market Indicators
OTC Market Forecast
Table: Taiwan’s OTC Market Forecast Indicators (TWDmn unless otherwise stated)
Export/Import Forecasts
Table: Taiwan’s Pharmaceutical Trade Indicators (US$mn)
Other Healthcare Data Forecasts
Table: Other Healthcare Data Trends
Key Risks To Our Forecast Scenario
Competitive Landscape
Table: Taiwan’s Pharmaceutical Market In Q406
Company Profiles
Multinationals
Pfizer
Sanofi-Aventis
GlaxoSmithKline
Novartis
Merck & Co
Bayer Schering Pharma
Indigenous Manufacturers
Yung Shin Pharmaceutical (YSP)
ScinoPharm Taiwan
Synmosa Biopharma
Life Star Pharmaceutical
EMO Biomedicine Corporation
Empax Pharma
Purzer Pharmaceutical
Taiwan Biotech Co
Country Snapshot: Taiwan Demographic Data
Section 1: Population
Table: Demographic Indicators, 2000-2030
Section 2: Labour Market And Spending Power
Table: Employment Indicators, 2000-2005
Table: Consumer Expenditure, 2000-2005 (US$)
Table: Average Annual Manufacturing Wages, 2005-2012
Our Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned Pfizer; Sanofi-Aventis; GlaxoSmithKline; Novartis; Merck & Co; Bayer Schering Pharma; Yung Shin Pharmaceutical (YSP); ScinoPharm Taiwan; Synmosa Biopharma; Life Star Pharmaceutical; EMO Biomedicine Corporation; Empax Pharma; Purzer Pharmaceutical; Taiwan Biotech Co


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/680267

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 29/11/2009 04:17:23
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Taiwan Pharmaceuticals and Healthcare Report Q4 2008
Web Address:
http://www.researchandmarkets.com/reports/680267
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 29/11/2009 04:17:23

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)